Last reviewed · How we verify
CAN008
At a glance
| Generic name | CAN008 |
|---|---|
| Also known as | APG101, Radiation |
| Sponsor | CANbridge Life Sciences Ltd. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Phase 2 Study of CAN008 in Subjects With GBM (PHASE2)
- To Evaluate the Efficacy and Safety of CAN008 Combined With Re-irradiation (rRT) for Treating Patients With Recurrent Glioblastoma (GBM) (PHASE2)
- A Study of CAN008 for Newly Diagnosed Glioblastoma Multiforme (PHASE1)
- CAN008 Biomarker CD95 Ligand and CpG2 Methylation in Chinese Patients With Glioblastoma
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CAN008 CI brief — competitive landscape report
- CAN008 updates RSS · CI watch RSS
- CANbridge Life Sciences Ltd. portfolio CI